These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Extreme weight gain in a youth with schizophrenia: risk/benefit considerations. Webster D; Devarajan S; Gallant J; Harris A; Kopala LC Schizophr Res; 2002 Jul; 56(1-2):187-9. PubMed ID: 12084432 [No Abstract] [Full Text] [Related]
23. Two new atypical antipsychotics: advantages and disadvantages. Lemon MD S D J Med; 1998 Aug; 51(8):285-6. PubMed ID: 9724957 [No Abstract] [Full Text] [Related]
24. The new antipsychotic compounds: is a clinical choice algorithm possible? Wirshing WC West J Med; 1998 Jul; 169(1):43-4. PubMed ID: 9682633 [No Abstract] [Full Text] [Related]
25. Cognitive behavior therapy for weight gain. Umbricht D; Flury H; Bridler R Am J Psychiatry; 2001 Jun; 158(6):971. PubMed ID: 11384925 [No Abstract] [Full Text] [Related]
29. Olanzapine appears haematologically safe in patients who developed blood dyscrasia on clozapine and risperidone. Dernovsek MZ; Tavcar R Int Clin Psychopharmacol; 2000 Jul; 15(4):237-8. PubMed ID: 10954065 [TBL] [Abstract][Full Text] [Related]
30. [Atypical antipsychotics]. Heeringa M; van Grootheest AC Ned Tijdschr Geneeskd; 2000 Oct; 144(43):2078-9. PubMed ID: 11072513 [No Abstract] [Full Text] [Related]
31. Panic disorder associated with clozapine. Bressan RA; Monteiro VB; Dias CC Am J Psychiatry; 2000 Dec; 157(12):2056. PubMed ID: 11097983 [No Abstract] [Full Text] [Related]
32. Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine. Markianos M; Hatzimanolis J; Lykouras L; Christodoulou GN Schizophr Res; 2002 Jul; 56(1-2):11-7. PubMed ID: 12084414 [TBL] [Abstract][Full Text] [Related]
33. Olanzapine-induced agranulocytosis: a case report and review of the literature. Tolosa-Vilella C; Ruiz-Ripoll A; Mari-Alfonso B; Naval-Sendra E Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb; 26(2):411-4. PubMed ID: 11817522 [TBL] [Abstract][Full Text] [Related]
34. Reversible neutropenia with olanzapine following clozapine-induced neutropenia. Thangadurai P; Jyothi KS; Gopalakrishnan R; Kuruvilla A; Jacob KS Am J Psychiatry; 2006 Jul; 163(7):1298. PubMed ID: 16816247 [No Abstract] [Full Text] [Related]
35. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Tollefson GD; Birkett MA; Kiesler GM; Wood AJ; Biol Psychiatry; 2001 Jan; 49(1):52-63. PubMed ID: 11163780 [TBL] [Abstract][Full Text] [Related]
36. Agranulocytosis in a second clozapine trial. Gupta S; Noor-Khan N; Frank B Psychiatr Serv; 1998 Aug; 49(8):1094. PubMed ID: 9712222 [No Abstract] [Full Text] [Related]
37. Olanzapine. Hale AS Br J Hosp Med; 1997 Nov 5-18; 58(9):442-5. PubMed ID: 9619205 [TBL] [Abstract][Full Text] [Related]
38. Response to letter of Professor Tim Lambert. Beasley CM Aust N Z J Psychiatry; 1999 Feb; 33(1):121-2. PubMed ID: 10197899 [No Abstract] [Full Text] [Related]
39. Rapid onset of dyskinesia induced by olanzapine. Yeh IN; Lin SK; Tsai CJ; Liu HC Psychiatry Clin Neurosci; 2003 Dec; 57(6):605-6. PubMed ID: 14629710 [No Abstract] [Full Text] [Related]
40. Olanzapine treatment in patients with typical and atypical neuroleptic-associated agranulocytosis. Finkel B; Lerner A; Oyffe I; Rudinski D; Sigal M; Weizman A Int Clin Psychopharmacol; 1998 May; 13(3):133-5. PubMed ID: 9690981 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]